Table 4.
Cox Regression Analysis for Progression-Free Survival in MDS Patients
| PFS variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| p | HR | 95% CI | p | HR | 95% CI | |
| Sex (male) | 0.024 | 1.61 | 1.07–2.43 | 0.067 | ||
| Age (>55 years) | 0.009 | 1.73 | 1.15–2.60 | 0.19 | ||
| WHO classification | 0.017 | 1.23 | 1.04–1.45 | 0.16 | ||
| Myelofibrosis | 0.002 | 2.02 | 1.30–3.15 | 0.003* | 1.99 | 1.27–3.11 |
| BM blasts | <0.001 | 1.14 | 1.10–1.18 | <0.001* | 1.14 | 1.10–1.19 |
| Monosomal karyotype | <0.001 | 3.28 | 1.81–5.96 | <0.001* | 3.05 | 1.67–5.56 |
| Complex karyotype | <0.001 | 4.07 | 2.12–7.85 | 0.41 | ||
| IPSS-R | <0.001 | 2.02 | 1.65–2.47 | 0.17 | ||
Note: *Significant difference.
Abbreviations: BM, bone marrow; CI, confidence interval; HR, hazard ratio; MDS, myelodysplastic syndrome; OS, overall survival; PFS, progression‐free survival; WHO, World Health Organization.